In this comprehensive overview, interventional cardiologist William Matthai, MD, considers the advances that have arrived in the cath lab in recent years to alter its traditional role as a site just for angioplasty and angiography. Dr. Matthai’s topics include new percutaneous interventions for structural heart disease, including TAVR and mitral valve procedures, medical management after these procedures and suggestions for anticoagulant management of atrial fibrillation patients, with a review of the novel oral anticoagulants that have recently entered the market. Dr. Matthai concludes with a review of the transcatheter heart valves and their supporting studies.

Related Links

• Clinical Briefing: Transcatheter Aortic Valve Replacement for Aortic Stenosis in Inoperable Patients
• Case Study: An 88-­year-­old man referred to Penn Interventional Cardiology after a decade of progressive heart failure (LVEF 30%) and a heavily calcified aortic valve opts for percutaneous transcatheter valve replacement.
• Dr. Matthai’s Profile